You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK):上半年總收入增加46.3%達到39.52億元 研發投入顯著增加
格隆匯 08-28 18:23

格隆匯8月28日丨信達生物(01801.HK)公佈中期業績,截至2024年6月30日止六個月,總收入為人民幣39.52億元,同比增加46.3%。報吿期內,產品收入為人民幣38.11億元,同比增長55.1%。收入的顯著增長主要得益於達伯舒®(信迪利單抗注射液)和其他產品的出色表現,以及新產品的加速增長及貢獻增加。截至2024年6月30日止六個月,總收入的毛利率為82.9%,較截至2023年6月30日止六個月的81.3%增加1.6個百分點。毛利率改善主要得益於產量的增加以及公司所生產藥物的生產成本的持續優化。

截至2024年6月30日止六個月,研究與開發(“研發”)開支為人民幣13.99億元,而截至2023年6月30日止六個月的研發開支為人民幣9.23億元。於報吿期內,公司持續戰略佈局研發投入,高效推進優先的後期資產和早期在研管線,以支持本公司可持續增長及全球創新的戰略目標。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account